Goldman Sachs Starts Phathom Pharmaceuticals (PHAT) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts PHAT Hot Sheet
Price: $5.92 +3.14%
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 12 | New: 3
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 12 | New: 3
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi initiates coverage on Phathom Pharmaceuticals (NASDAQ: PHAT) with a Neutral rating and a price target of $32.00.
For an analyst ratings summary and ratings history on Phathom Pharmaceuticals click here. For more ratings news on Phathom Pharmaceuticals click here.
Shares of Phathom Pharmaceuticals closed at $24.27 yesterday.
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT)
- Wedbush Starts Nuscale Power (SMR) at Underperform
- Northland Starts Aeluma (ALMU) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
